Skip to content

Author

D. Doroshow

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Patterns of treatment-related adverse events and treatment discontinuation in phase III oncology clinical trials.

466 Background: Treatment-related adverse events (TRAEs) are a common cause of discontinuation in cancer clinical trials. Although TRAEs are routinely documented, the relative contributions of patients (pts), clinicians, and protocol-mandated requirements to these decisions remain poorly characterized. We sough...

Hannah Pearl, Breanna Yi-Zhu Yang, Jacob Abrahams et al. · 0 citations
Open access Oct 2026

Multidimensional barriers and facilitators to early phase clinical trial (EPCT) participation among diverse patients with advanced solid tumors.

Barriers to EPCT participation among a group of minoritized trial participants and caregivers were driven by a combination of limited awareness, language barriers, logistical intensity, fear of uncertainty, and historical distrust.

I. Yao, Marina Serrano Fernandez, Taira Anderson et al. · 0 citations
Review Open access Oct 2026

Patient, caregiver, and clinician perspectives to inform a peer community navigator intervention for early-phase clinical trials participation.

118 Background: Black and Hispanic patients remain underrepresented in early-phase cancer clinical trials (EPCTs), limiting equitable access to novel therapies. Building on a pilot study of a community navigator (CN)-led intervention that was feasible, acceptable, and had positive stakeholder feedback, we condu...

Marina Serrano Fernandez, I. Yao, Taira Anderson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.